Molecular targets for the rational design of drugs to inhibit SARS coronavirus

Despite years of research, the precise determinants of coronavirus replication and pathogenesis remain unidentified. What is known of the pathogenesis of the severe acute respiratory syndrome coronavirus (SARS-CoV) is limited, but clinical observations suggest that both viral-induced cytotoxicity an...

Descripción completa

Detalles Bibliográficos
Autores principales: Brockway, Sarah M., Denison, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2004
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105069/
https://www.ncbi.nlm.nih.gov/pubmed/32288772
http://dx.doi.org/10.1016/j.ddmec.2004.08.016
_version_ 1783512335445393408
author Brockway, Sarah M.
Denison, Mark R.
author_facet Brockway, Sarah M.
Denison, Mark R.
author_sort Brockway, Sarah M.
collection PubMed
description Despite years of research, the precise determinants of coronavirus replication and pathogenesis remain unidentified. What is known of the pathogenesis of the severe acute respiratory syndrome coronavirus (SARS-CoV) is limited, but clinical observations suggest that both viral-induced cytotoxicity and host immune-mediated destruction contribute to the severity of disease. This summary discusses recent advances in coronavirus research that will facilitate the identification of crucial molecular targets for the rational design of SARS therapeutics.
format Online
Article
Text
id pubmed-7105069
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71050692020-03-31 Molecular targets for the rational design of drugs to inhibit SARS coronavirus Brockway, Sarah M. Denison, Mark R. Drug Discov Today Dis Mech Article Despite years of research, the precise determinants of coronavirus replication and pathogenesis remain unidentified. What is known of the pathogenesis of the severe acute respiratory syndrome coronavirus (SARS-CoV) is limited, but clinical observations suggest that both viral-induced cytotoxicity and host immune-mediated destruction contribute to the severity of disease. This summary discusses recent advances in coronavirus research that will facilitate the identification of crucial molecular targets for the rational design of SARS therapeutics. Elsevier Ltd. 2004-11 2004-10-03 /pmc/articles/PMC7105069/ /pubmed/32288772 http://dx.doi.org/10.1016/j.ddmec.2004.08.016 Text en Copyright © 2004 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Brockway, Sarah M.
Denison, Mark R.
Molecular targets for the rational design of drugs to inhibit SARS coronavirus
title Molecular targets for the rational design of drugs to inhibit SARS coronavirus
title_full Molecular targets for the rational design of drugs to inhibit SARS coronavirus
title_fullStr Molecular targets for the rational design of drugs to inhibit SARS coronavirus
title_full_unstemmed Molecular targets for the rational design of drugs to inhibit SARS coronavirus
title_short Molecular targets for the rational design of drugs to inhibit SARS coronavirus
title_sort molecular targets for the rational design of drugs to inhibit sars coronavirus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105069/
https://www.ncbi.nlm.nih.gov/pubmed/32288772
http://dx.doi.org/10.1016/j.ddmec.2004.08.016
work_keys_str_mv AT brockwaysarahm moleculartargetsfortherationaldesignofdrugstoinhibitsarscoronavirus
AT denisonmarkr moleculartargetsfortherationaldesignofdrugstoinhibitsarscoronavirus

Ejemplares similares